PROS1 and prostate cancer: Forty-four patients with increased PSA and mostly existing metastases (>80%) were recruited, and the results showed a superior immunogenicity rate induced by the vaccine in prostate cancer patients; antigen-specific T cells were observed in approximately 80% of patients independently of their HLA background, and approximately 58% reacted against multiple antigens.